Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a μ genotype

Virology

Volumn 452-453, Issue , 2014, Pages 279-286

  Da Silva, Diane M ^a,b   Movius, Carly A ^a   Raff, Adam B ^b,c   Brand, Heike E ^b   Skeate, Joseph G ^a   Wong, Michael K ^a   Kast, W Martin ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antigen presentation; Antigen presenting cell; Human papillomavirus; Immune escape; Immune suppression; Langerhans cell; Migration

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; HUMAN PAPILLOMAVIRUS; IMMUNE ESCAPE; IMMUNE SUPPRESSION; LANGERHANS CELL; MIGRATION;

BIOLOGICAL EVOLUTION; CYTOKINES; DOWN-REGULATION; GENOTYPE; HUMANS; LANGERHANS CELLS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84893939463     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.01.031     Document Type: Article

References (59)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
2. Bedoui S., Whitney P.G., Waithman J., Eidsmo L., Wakim L., Caminschi I., Allan R.S., Wojtasiak M., Shortman K., Carbone F.R., Brooks A.G., Heath W.R. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 2009, 10(5):488-495.
3. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 2005, 32(Suppl. 1):S1-S6.
4. Bobr A., Olvera-Gomez I., Igyarto B.Z., Haley K.M., Hogquist K.A., Kaplan D.H. Acute ablation of Langerhans cells enhances skin immune responses. J. Immunol. 2010, 185(8):4724-4728.
5. Brown D.R., Bryan J.T. Abnormalities of cornified cell envelopes isolated from human papillomavirus type 11-infected genital epithelium. Virology 2000, 271(1):65-70.
6. Bryan J.T., Brown D.R. Transmission of human papillomavirus type 11 infection by desquamated cornified cells. Virology 2001, 281(1):35-42.
7. Buck, C.B., Thompson, C.D., 2007. Production of papillomavirus-based gene transfer vectors, John Wiley & Sons, Curr. Protoc. Cell Biol. 37:26.1.1-26.1.19. http://dx.doi.org/10.1002/0471143030.cb2601s37.
8. Cunningham A.L., Carbone F., Geijtenbeek T.B. Langerhans cells and viral immunity. Eur. J. Immunol. 2008, 38(9):2377-2385.
9. De Koning M.N., Struijk L., Bavinck J.N., Kleter B., ter Schegget J., Quint W.G., Feltkamp M.C. Betapapillomaviruses frequently persist in the skin of healthy individuals. J. Gen. Virol. 2007, 88(Pt 5):1489-1495.
10. De Koning M.N., Weissenborn S.J., Abeni D., Bouwes Bavinck J.N., Euvrard S., Green A.C., Harwood C.A., Naldi L., Neale R., Nindl I., Proby C.M., Quint W.G., Sampogna F., ter Schegget J., Struijk L., Wieland U., Pfister H.J., Feltkamp M.C. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J. Gen. Virol. 2009, 90(Pt 7):1611-1621.
11. De Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology 2013, 445:2-10.
12. Dhodapkar M.V., Steinman R.M. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002, 100(1):174-177.
13. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001, 193(2):233-238.
14. Duluc D., Gannevat J., Anguiano E., Zurawski S., Carley M., Boreham M., Stecher J., Dullaers M., Banchereau J., Oh S. Functional diversity of human vaginal APC subsets in directing T-cell responses. Mucosal Immunol. 2013, 6(3):626-638.
15. Fahey L.M., Raff A.B., Da Silva D.M., Kast W.M. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J. Immunol. 2009, 183(10):6151-6156.
16. Fausch S.C., Da Silva D.M., Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003, 63(13):3478-3482.
17. Fausch S.C., Da Silva D.M., Kast W.M. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine 2005, 23(14):1720-1729.
18. Fausch S.C., Da Silva D.M., Rudolf M.P., Kast W.M. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 2002, 169(6):3242-3249.
19. Fausch S.C., Fahey L.M., Da Silva D.M., Kast W.M. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J. Immunol. 2005, 174(11):7172-7178.
20. Fothergill T., McMillan N.A. Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 2006, 352(2):319-328.
21. Frauwirth K.A., Alegre M.L., Thompson C.B. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J. Immunol. 2000, 164(6):2987-2993.
22. Geissmann F., Prost C., Monnet J.P., Dy M., Brousse N., Hermine O. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J. Exp. Med. 1998, 187(6):961-966.
23. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., Abrahamsen M., Inserra P., Olvera S., Hatch K. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women[U+05F3]s Health Study. J. Infect. Dis. 2002, 186(4):462-469.
24. Handisurya A., Day P.M., Thompson C.D., Buck C.B., Kwak K., Roden R.B., Lowy D.R., Schiller J.T. Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012, 433(2):385-394.
25. Hazard K., Karlsson A., Andersson K., Ekberg H., Dillner J., Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J. Investig. Dermatol. 2007, 127(1):116-119.
26. Henri S., Poulin L.F., Tamoutounour S., Ardouin L., Guilliams M., de Bovis B., Devilard E., Viret C., Azukizawa H., Kissenpfennig A., Malissen B. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 2010, 207(1):189-206.
27. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338(7):423-428.
28. Iijima N., Goodwin E.C., Dimaio D., Iwasaki A. High-risk human papillomavirus E6 inhibits monocyte differentiation to Langerhans cells. Virology 2013, 444(1-2):257-262.
29. Jablonska S., Majewski S., Obalek S., Orth G. Cutaneous warts. Clin. Dermatol. 1997, 15(3):309-319.
30. Kanodia S., Fahey L.M., Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 2007, 7(1):79-89.
31. Kaplan D.H., Jenison M.C., Saeland S., Shlomchik W.D., Shlomchik M.J. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005, 23(6):611-620.
32. Kawana Y., Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 2001, 75(5):2331-2336.
33. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., Lowy D.R., Schiller J.T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 1993, 67(12):6929-6936.
34. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992, 89(24):12180-12184.
35. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., Reiter Y., Banchereau J., Ueno H. Functional specializations of human epidermal langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29(3):497-510.
36. Kulmala S.M., Shabalova I.P., Petrovitchev N., Syrjanen K.J., Gyllensten U.B., Johansson B.C., Syrjanen S.M. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol. Biomark. Prev. 2007, 16(1):17-22.
37. Leong C.M., Doorbar J., Nindl I., Yoon H.S., Hibma M.H. Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types. Br. J. Dermatol. 2010, 163(6):1253-1263.
38. Leong C.M., Doorbar J., Nindl I., Yoon H.S., Hibma M.H. Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections. J. Investig. Dermatol. 2010, 130(2):472-480.
39. Lizano M., Berumen J., Garcia-Carranca A. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch. Med. Res. 2009, 40(6):428-434.
40. Lowe J., Panda D., Rose S., Jensen T., Hughes W.A., Tso F.Y., Angeletti P.C. Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. Virol. J. 2008, 5:150.
41. Moscicki A.B., Ellenberg J.H., Farhat S., Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J. Infect. Dis. 2004, 190(1):37-45.
42. Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A., Coutlee F., Franco E.L. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomark. Prev. 2003, 12(6):485-490.
43. Roden R.B., Greenstone H.L., Kirnbauer R., Booy F.P., Jessie J., Lowy D.R., Schiller J.T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 1996, 70(9):5875-5883.
44. Romani N., Brunner P.M., Stingl G. Changing views of the role of Langerhans cells. J. Invest. Dermatol. 2012, 132(3 Pt 2):872-881.
45. Romani N., Holzmann S., Tripp C.H., Koch F., Stoitzner P. Langerhans cells-dendritic cells of the epidermis. Apmis 2003, 111(7-8):725-740.
46. Saeki H., Moore A.M., Brown M.J., Hwang S.T. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. (Baltimore, Md.: 1950) 1999, 162(5):2472-2475.
47. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., Duarte-Franco E., Rohan T.E., Ferenczy A., Villa L.L., Franco E.L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA: J. Am. Med. Assoc. 2001, 286(24):3106-3114.
48. Scott M.E., Ma Y., Kuzmich L., Moscicki A.B. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int. J. Cancer 2009, 124(6):1379-1383.
49. Shklovskaya E., O'Sullivan B.J., Ng L.G., Roediger B., Thomas R., Weninger W., Fazekas de St Groth B. Langerhans cells are precommitted to immune tolerance induction. Proc. Natl. Acad. Sci. USA 2011, 108(44):18049-18054.
50. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 2007, 121(3):621-632.
51. Stanley M.A., Pett M.R., Coleman N. HPV: from infection to cancer. Biochem. Soc. Trans. 2007, 35(Pt 6):1456-1460.
52. van der Burg S.H., Piersma S.J., de Jong A., van der Hulst J.M., Kwappenberg K.M., van den Hende M., Welters M.J., Van Rood J.J., Fleuren G.J., Melief C.J., Kenter G.G., Offringa R. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl. Acad. Sci. USA 2007, 104(29):12087-12092.
53. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., ShahK V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol 1999, 189:12-19.
54. Winer R.L., Hughes J.P., Feng Q., Xi L.F., Cherne S., O'Reilly S., Kiviat N.B., Koutsky L.A. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol. Biomark. Prev. 2011, 20(4):699-707.
55. Woodham A.W., Da Silva D.M., Skeate J.G., Raff A.B., Ambroso M.R., Brand H.E., Isas J.M., Langen R., Kast W.M. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 2012, 7(8):e43519.
56. Woodham, A.W., Raff, A.B., Raff, L.M., Da Silva, D.M., Yan, L., Skeate, J.G., Wong, M.K., Lin, Y.G., Kast, W.M., 2014. Suppression of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer (submitted for publication).
57. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., Thomas R. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 2004, 324(2):297-310.
58. Yang R., Day P.M., Yutzy W.H., Lin K.Y., Hung C.F., Roden R.B. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J. Virol. 2003, 77(6):3531-3541.
59. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185(1):251-257.